Remove BMI Remove Cholesterol Remove Public Health
article thumbnail

Global Trends in Cardiovascular Diseases: Insights from the 2023 Almanac

Cardiology Update

Metabolic risks, including high systolic blood pressure, high LDL cholesterol, high BMI, high fasting plasma glucose, and kidney dysfunction, contribute substantially to age-standardized CVD disability-adjusted life years (DALYs). The findings have significant implications for clinical and public health practice and research.

article thumbnail

FDA Approves Wegovy for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity

DAIC

The estimated relative risk reduction of MACE was 20% vs placebo (HR 0.80 [95% CI: 0.72, 0.90] p 1,2 The reduction of MACE with Wegovy was not impacted by age, sex, race, ethnicity, baseline BMI, or level of renal function impairment. in patients randomized to Wegovy 2.4 mg and 36.4% of patients receiving placebo. 2 What is Wegovy?

Obesity 111